Tratamientos de primera línea para pacientes estadio IV con adenocarcinoma pulmonar de mutación EGFR
First-line treatments for stage IV patients with EGFR-mutated lung adenocarcinoma
Rev. Hosp. Clin. Univ. Chile; 32 (3), 2021
Lung cancer is one of the leading causes of death in the world. Current treatments act directly on the signal transduction pathways in cancer cells, mainly. One of the main pathways is associated with the Epidermal Growth Factor (EGFR), whose mutations leads to uncontrolled cell proliferation and a highe...